NTI endorses the bipartisan Biosecurity Modernization and Innovation Act of 2026, led by Senators Tom Cotton (R-AR) and Amy Klobuchar (D-MN). This bill creates an important opportunity to incentivize a safe and secure U.S. bioeconomy through strengthened biosecurity policy.
New START, the last remaining arms control treaty capping U.S. and Russian nuclear arsenals, expires on February 5. This marks the beginning of a dangerous new era. For the first time in several decades, there will be no limits on nuclear weapons, less visibility into Russian nuclear weapons activities, and fewer tools to manage a crisis between the world’s two largest nuclear powers.
Global health security —the ability to protect against the negative impacts of disease outbreaks — is too important to be left solely to the public sector. Industry has a vital interest in helping countries better prepare for future epidemics and pandemics.
Funding from the Bezos Earth Fund will support the creation of an orderbook for new nuclear reactor builds in the United States.
New NTI | bio paper calls on tool developers and other AIxBio stakeholders to implement a managed access approach—allowing only validated users to access those biological AI models that contribute to biosecurity risks—to help reduce the risk that such tools will be deliberately misused to cause harm.
Managed access will be critical for reducing biosecurity risks related to the misuse of biological AI tools. By working to develop best practices for each element of this framework—risk levels, tiered access, and practices to verify legitimacy—developers of biological AI tools and the broader life sciences community can reduce risks while maintaining the benefits of these tools.
As the last remaining U.S.-Russia nuclear limitations treaty expires on Feb. 5, an overwhelming majority of Americans (91 percent) say the United States should negotiate a new agreement with Russia to either maintain current limits on nuclear weapons or further reduce both countries’ arsenals.
Mirror life operates outside the assumptions that underpin modern biosafety, biosecurity, and medical surveillance, meaning the policy challenge is not only what to regulate — but how to govern a technology that doesn’t yet exist.
Unless the United States and Russia agree to maintain limits on their forces, the world will enter a period of potentially unconstrained nuclear build-ups.
With the New START treaty set to expire February 5, President Trump has a real opportunity to stop a dangerous nuclear arms race. This is the moment for smart leadership and strong dealmaking.
Sign up for regular updates on innovative, real-world solutions to existential threats.
